Similar Papers

Paper Title
Journal
Date
Author
Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Naval Daver ... Jessica K Altman
Blood | VOL. 138
Naval Daver, et. al.Naval Daver ... Jessica K Altman
05 Nov 2021
Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies
Naveen Pemmaraju ...
Blood | VOL. 138
Naveen Pemmaraju, et. al.Naveen Pemmaraju ...
05 Nov 2021
Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells
Nora Zieger ...
Blood | VOL. 138
Nora Zieger, et. al.Nora Zieger ...
05 Nov 2021
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
Peter Paschka ...
Blood | VOL. 136
Peter Paschka, et. al.Peter Paschka ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
The JAK2 46/1 haplotype influences PD-L1 expression.
Gonzalo Carreño-Tarragona ... Miguel Manzanares
Blood | VOL. -
Gonzalo Carreño-Tarragona, et. al.Gonzalo Carreño-Tarragona ... Miguel Manzanares
07 Feb 2025
Targeting cell surface VISTA expression on allospecific naïve T cells promotes tolerance.
Brent H Koehn ... Bruce R Blazar
Blood | VOL. -
Brent H Koehn, et. al.Brent H Koehn ... Bruce R Blazar
07 Feb 2025
Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
Ioannis Mantzaris ... Eric J Feldman
Blood | VOL. -
Ioannis Mantzaris, et. al.Ioannis Mantzaris ... Eric J Feldman
07 Feb 2025
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.